EP0105360A4 - Anticorps ayant des doubles specificites, leur preparation et utilisation. - Google Patents

Anticorps ayant des doubles specificites, leur preparation et utilisation.

Info

Publication number
EP0105360A4
EP0105360A4 EP19830901672 EP83901672A EP0105360A4 EP 0105360 A4 EP0105360 A4 EP 0105360A4 EP 19830901672 EP19830901672 EP 19830901672 EP 83901672 A EP83901672 A EP 83901672A EP 0105360 A4 EP0105360 A4 EP 0105360A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
preparation
uses therefor
dual specificities
specificities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19830901672
Other languages
German (de)
English (en)
Other versions
EP0105360A1 (fr
Inventor
Joanne Martinis
Richard M Bartholomew
Gary S David
Thomas H Adams
James M Frincke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of EP0105360A1 publication Critical patent/EP0105360A1/fr
Publication of EP0105360A4 publication Critical patent/EP0105360A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP19830901672 1982-04-12 1983-04-12 Anticorps ayant des doubles specificites, leur preparation et utilisation. Ceased EP0105360A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12
US367784 1982-04-12

Publications (2)

Publication Number Publication Date
EP0105360A1 EP0105360A1 (fr) 1984-04-18
EP0105360A4 true EP0105360A4 (fr) 1986-07-08

Family

ID=23448582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19830901672 Ceased EP0105360A4 (fr) 1982-04-12 1983-04-12 Anticorps ayant des doubles specificites, leur preparation et utilisation.

Country Status (11)

Country Link
EP (1) EP0105360A4 (fr)
JP (2) JPH0753119B2 (fr)
AT (1) AT394577B (fr)
AU (1) AU550486B2 (fr)
CA (1) CA1213229A (fr)
CH (1) CH672796A5 (fr)
ES (7) ES8504461A1 (fr)
FI (2) FI900212A0 (fr)
GB (4) GB2128631B (fr)
IT (1) IT1219778B (fr)
WO (1) WO1983003679A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
EP0467416A1 (fr) * 1983-09-01 1992-01-22 Hybritech Incorporated Compositions d'anticorps d'agents therapeutiques à période de demi-vie sérique prolongée
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPH0617909B2 (ja) * 1984-04-23 1994-03-09 ボストン バイオメディカル リサーチ インスティテュート，インコーポレイテッド 双特異性抗体決定子
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
EP0241907A3 (fr) 1986-04-14 1989-09-13 The General Hospital Corporation Anticorps hétérobifonctionnels et méthode d'utilisation
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
CA2006408A1 (fr) * 1988-12-27 1990-06-27 Susumu Iwasa Anticorps monoclaux bispecifiques, production et utilisation
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
WO1990012109A1 (fr) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Anticorps monoclonaux s'associant a des complexes de platine
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
EP0515571B1 (fr) * 1990-02-16 1998-12-02 Boston Biomedical Research Institute Reactifs hybrides pouvant liberer des molecules de maniere selective dans des cellules
TW212184B (fr) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
IE921342A1 (en) * 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
EP0937146A2 (fr) * 1996-09-20 1999-08-25 The General Hospital Corporation Composition et procede pour ameliorer la fibrinolyse au moyen d'anticorps d'alpha-2-antiplasmine
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
NZ549962A (en) 2004-03-16 2010-04-30 Univ Temple Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
WO2006132670A2 (fr) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatines comportant une unite d'acide aminobenzoique au n-terminal
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
WO2008070593A2 (fr) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Agents se liantà des cibles variables et utilisations de ceux-ci
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (fr) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions et procédés de ciblage et d'administration d'agents thérapeutiques dans des cellules
WO2014089177A2 (fr) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
JP6473418B2 (ja) * 2013-10-10 2019-02-20 幸成 加藤 抗ポドプラニン抗体
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6486316B2 (ja) 2015-11-03 2019-03-20 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018209239A1 (fr) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Dérivés d'agélastatine puissants en tant que modulateurs de l'invasion et de la métastase du cancer
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7156653B2 (ja) 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
MX2021013657A (es) 2019-05-10 2022-02-21 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
WO2022182415A1 (fr) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Dérivés d'himastatine, leurs procédés de préparation et leurs utilisations
JP2024527551A (ja) 2021-06-29 2024-07-25 シージェン インコーポレイテッド 非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.L. Reading on symposium on Hybridomas and Cellular Immortality, 5-6 Nov. 1981, Houston; in proceedings "Hybridomas and Cellular Immortality", Plenum Press 1983, Tom and Allison Eds.; *

Also Published As

Publication number Publication date
IT1219778B (it) 1990-05-24
ES537257A0 (es) 1986-04-01
FI900212A7 (fi) 1990-01-15
ES538727A0 (es) 1986-02-01
JP2562002B2 (ja) 1996-12-11
ES8606655A1 (es) 1986-04-01
AT394577B (de) 1992-05-11
GB2169921A (en) 1986-07-23
GB2168998A (en) 1986-07-02
GB2128631B (en) 1987-02-25
CH672796A5 (fr) 1989-12-29
GB8530308D0 (en) 1986-01-22
AU550486B2 (en) 1986-03-20
IT8320548A0 (it) 1983-04-12
JPH0753600A (ja) 1995-02-28
EP0105360A1 (fr) 1984-04-18
GB2169921B (en) 1987-03-04
JPH0753119B2 (ja) 1995-06-07
GB2167086A (en) 1986-05-21
JPS6312276A (ja) 1988-01-19
ES521370A0 (es) 1985-04-16
ES8604424A1 (es) 1986-02-01
GB8332646D0 (en) 1984-01-11
GB2167086B (en) 1987-03-04
ES8607386A1 (es) 1986-05-16
FI834529A7 (fi) 1983-12-09
ES8506091A1 (es) 1985-06-16
FI900212A0 (fi) 1990-01-15
ATA901883A (de) 1991-10-15
ES533931A0 (es) 1985-06-16
FI834529A0 (fi) 1983-12-09
CA1213229A (fr) 1986-10-28
ES8503441A1 (es) 1985-02-16
ES8504461A1 (es) 1985-04-16
AU1555983A (en) 1983-11-04
ES527963A0 (es) 1985-02-16
ES545247A0 (es) 1986-05-16
FI834529L (fi) 1983-12-09
GB8530309D0 (en) 1986-01-22
GB2128631A (en) 1984-05-02
WO1983003679A1 (fr) 1983-10-27
GB2168998B (en) 1987-03-04
ES533930A0 (es) 1985-12-01
GB8530310D0 (en) 1986-01-22
ES8603080A1 (es) 1985-12-01

Similar Documents

Publication Publication Date Title
EP0105360A4 (fr) Anticorps ayant des doubles specificites, leur preparation et utilisation.
AR242417A1 (es) Procedimiento para la preparacion de pirrolo-¡3,4-c¿-pirrolenos
ZA852438B (en) Antibodies,manufacture and use
DE3381294D1 (en) Brueckenwiderlager.
DE3382383D1 (en) Interleukin-2-polypeptide.
AU4493685A (en) Polyclonal antibodies, preparation and use
CS149383A2 (en) Zpusob vyroby methylterc.butyletheru
DE3382106D1 (en) Polyacetalharzmischungen.
EP0105346A4 (fr) Antigene synthetique du picornavirus.
DE3382031D1 (en) Polypeptide.
IL70968A (en) Urea-linked immunogens,their preparation and antibodies thereto
EP0122268A4 (fr) Organes structuraux.
EP0131627A4 (fr) Antigenes specifiques de la famille cea (antigene carcino-embryonaire), anticorps specifiques de ces antigenes et leurs procedes d'utilisation.
AU1270583A (en) 3-azolyl-1,2-diaryl-1-halogenoprop-1-enes
AU563881B2 (en) Carbacycline, preparation and utilization thereof
DE3381195D1 (en) Differentialsiebring.
IL69531A0 (en) Antibodies against bacterial peptidoglycans,their preparation and determination
IL83342A0 (en) Monoclonal antibodies,their preparation and their use
DE3381931D1 (en) Spruehvorrichtung.
AU1093783A (en) G.h. releasing peptide
OA07604A (en) Improved melaminylthioarsenites.
EP0334958A4 (fr) Anticorps monoclonaux.
Randell Eating right
IE841235L (en) Immunological methods - enzyme preparations.
AU612122C (en) Monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19831210

AK Designated contracting states

Designated state(s): BE DE FR NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19860708

17Q First examination report despatched

Effective date: 19880606

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19931210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DAVID, GARY S.

Inventor name: FRINCKE, JAMES M.

Inventor name: ADAMS, THOMAS H.

Inventor name: MARTINIS, JOANNE

Inventor name: BARTHOLOMEW, RICHARD M.